Publications

Nature

γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.

01-01-2023

Key

Nature medicine

Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial.

01-12-2020

Key

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

Key

Cell

Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids.

06-09-2018

Key

Journal of immunology (Baltimore, Md. : 1950)

ITPK1 Sensitizes Tumor Cells to IgA-dependent Neutrophil Killing In Vivo.

15-10-2024

Nature medicine

Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.

16-09-2024

Nature medicine

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

15-09-2024

Nature

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy.

01-08-2024

Cancer discovery

IL2 Targeted to CD8+ T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity.

01-07-2024

Cancer discovery

CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool.

01-07-2024

Cell reports

Gene and protein sequence features augment HLA class I ligand predictions.

25-06-2024

The New England journal of medicine

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

06-06-2024

Science (New York, N.Y.)

DNA damage induces p53-independent apoptosis through ribosome stalling.

17-05-2024

Nature medicine

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-05-2024

Nature biotechnology

Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.

23-04-2024

Nature reviews. Clinical oncology

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma.

01-03-2024

Nature medicine

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

01-02-2024

Cancer cell

Distinct spatiotemporal dynamics of CD8⁺ T cell-derived cytokines in the tumor microenvironment.

08-01-2024

Cancer cell

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.

09-10-2023

Cancer discovery

Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment.

05-10-2023

Nature biotechnology

Identification of patient-specific CD4⁺ and CD8⁺ T cell neoantigens through HLA-unbiased genetic screens.

01-06-2023

Cancer immunology, immunotherapy : CII

The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer.

01-06-2023

STAR protocols

Protocol for ex vivo culture of patient-derived tumor fragments.

06-05-2023

Nature communications

DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age.

17-04-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.

01-04-2023

Nature cancer

PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.

01-04-2023

Cell reports. Medicine

An adverse tumor-protective effect of IDO1 inhibition.

21-02-2023

BMC cancer

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.

30-12-2022

The New England journal of medicine

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.

08-12-2022

Clinical cancer research : an official journal of the American Association for Cancer Research

PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.

14-11-2022

Med (New York, N.Y.)

Next generation T cell therapies for solid cancers.

14-10-2022

Cancer discovery

When Cancer Cells Become the Enablers of an Antitumor Immune Response.

05-10-2022

Immuno-oncology technology

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.

01-09-2022

Nature immunology

Author Correction: Replicative history marks transcriptional and functional disparity in the CD8⁺ T cell memory pool.

01-07-2022

Nature reviews. Immunology

The precursors of CD8⁺ tissue resident memory T cells: from lymphoid organs to infected tissues.

01-05-2022

Nature immunology

Replicative history marks transcriptional and functional disparity in the CD8⁺ T cell memory pool.

01-05-2022

Nature biotechnology

T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes.

01-04-2022

Oncoimmunology

QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment.

22-03-2022

Current opinion in immunology

Safety switches for adoptive cell therapy.

01-02-2022

Science (New York, N.Y.)

Tertiary lymphoid structures in cancer.

07-01-2022

Nature communications

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.

22-12-2021

Science (New York, N.Y.)

An atlas of intratumoral T cells.

17-12-2021

Cell reports

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8⁺ T cells.

16-11-2021

Nature chemical biology

Single-cell analysis of regions of interest (SCARI) using a photosensitive tag.

01-11-2021

Proceedings of the National Academy of Sciences of the United States of America

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.

26-10-2021

Human gene therapy

Multimodular Optimization of Chemically Regulated T Cell Switches Demonstrates Flexible and Interchangeable Nature of Immune Cell Signaling Domains.

01-10-2021

Cancer discovery

Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy.

01-10-2021

Cancer immunology research

CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function.

01-09-2021

Cold Spring Harbor perspectives in biology

Formation of Tissue-Resident CD8⁺ T-Cell Memory.

02-08-2021

Journal for immunotherapy of cancer

HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial.

01-08-2021